The authors regret that some Author information was incorrectly given in the published article. Author Manuel Zamparini was missed in the Author list, and the listed affiliation for Paola Queirolo was incorrect. The full and correct details for the Authors are: Paola Queirolo Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy Manuel Zamparini University of Brescia, Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, ASST-Spedali Civili, Brescia, Lombardia, ItalyThe Authors also note that values in the first column of Table 4 were mistakenly reversed for ‘Antibiotic intake (within 1 month before therapy)’ and ‘Haemoglobin’. The correct table in full is given here.

Baggi, A., Quaglino, P., Rubatto, M., Depenni, R., Guida, M., Ascierto, P. A., Trojaniello, C., Queirolo, P., Saponara, M., Peris, K., Spagnolo, F., Bianchi, L., De Galitiis, F., Potenza, M. C., Proietti, I., Marconcini, R., Botticelli, A., Barbieri, V., Licitra, L., Alfieri, S., Ficorella, C., Cortellini, A., Fargnoli, M. C., Troiani, T., Tondulli, L., Zamparini, M., Bossi, P., Corrigendum: “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” (European Journal of Cancer (2021) 157 (250–258), (S0959804921005360), (10.1016/j.ejca.2021.08.018)), <<EUROPEAN JOURNAL OF CANCER>>, 2022; 166 (may): 309-310. [doi:10.1016/j.ejca.2022.02.027] [http://hdl.handle.net/10807/206063]

Corrigendum: “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” (European Journal of Cancer (2021) 157 (250–258), (S0959804921005360), (10.1016/j.ejca.2021.08.018))

Peris, K.;Barbieri, V.;Fargnoli, M. C.;
2022

Abstract

The authors regret that some Author information was incorrectly given in the published article. Author Manuel Zamparini was missed in the Author list, and the listed affiliation for Paola Queirolo was incorrect. The full and correct details for the Authors are: Paola Queirolo Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy Manuel Zamparini University of Brescia, Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, ASST-Spedali Civili, Brescia, Lombardia, ItalyThe Authors also note that values in the first column of Table 4 were mistakenly reversed for ‘Antibiotic intake (within 1 month before therapy)’ and ‘Haemoglobin’. The correct table in full is given here.
Inglese
Baggi, A., Quaglino, P., Rubatto, M., Depenni, R., Guida, M., Ascierto, P. A., Trojaniello, C., Queirolo, P., Saponara, M., Peris, K., Spagnolo, F., Bianchi, L., De Galitiis, F., Potenza, M. C., Proietti, I., Marconcini, R., Botticelli, A., Barbieri, V., Licitra, L., Alfieri, S., Ficorella, C., Cortellini, A., Fargnoli, M. C., Troiani, T., Tondulli, L., Zamparini, M., Bossi, P., Corrigendum: “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” (European Journal of Cancer (2021) 157 (250–258), (S0959804921005360), (10.1016/j.ejca.2021.08.018)), <<EUROPEAN JOURNAL OF CANCER>>, 2022; 166 (may): 309-310. [doi:10.1016/j.ejca.2022.02.027] [http://hdl.handle.net/10807/206063]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/206063
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact